GlassScriptPhysician profile
Constance Maybell Sweet
NPI 1134103666
$8,317.36
in general payments reported to CMS, 2019-2025
37 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $583 · 2021: $1,939 · 2022: $1,507 · 2023: $1,277 · 2024: $1,239 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.48 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,450.49 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,445.00 | 2019-2025 | Jardiance, Mounjaro |
| Amgen INC. | $1,048.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $479.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $408.37 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $350.22 | 2019-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $317.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $245.01 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $195.98 | 2025 | Auvelity |
| Allergan, INC. | $195.34 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $175.43 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $148.19 | 2024-2025 | Nuzyra, Xhance |
| Merck Sharp & Dohme LLC | $129.21 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.72 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.